Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise

Cost Effectiveness and Resource Allocation : C/E
Hua NianBin Wu

Abstract

To investigate the long-term economic outcome of dapagliflozin versus metformin in Chinese patients with type 2 diabetes mellitus (T2DM) whose diet and exercise have not provided sufficient glycemic control. An economic analysis of dapagliflozin versus metformin was conducted by using the Chinese Outcomes Model for T2DM with a time horizon of lifetime, which was developed and validated based on the Chinese population. The efficacy data of lowering HbA1c of dapagliflozin and metformin was derived from a network meta-analysis. Other clinical, cost and utility inputs were obtained from published sources. Lifetime discounted quality-adjusted life-years, cost, and incremental cost-effectiveness ratio were measured. The uncertainty was facilitated by one-way and probabilistic sensitivity analyses. The comparison of metformin and dapagliflozin in Chinese patients with insufficient glycemic control by diet and exercise showed that dapagliflozin was more costly and produced fewer health benefits in our simulated cohort. The sensitivity analyses indicated that the results were robust. Dapagliflozin is not likely to be cost-effective compared with metformin for Chinese patients with T2DM inadequately controlled with diet and exercise.

References

Oct 1, 2001·Expert Review of Pharmacoeconomics & Outcomes Research·B A Craig, M A Black
Mar 26, 2010·The New England Journal of Medicine·Wenying YangUNKNOWN China National Diabetes and Metabolic Disorders Study Group
Jul 11, 2012·Expert Opinion on Pharmacotherapy·Shamsa Ali, Vivian Fonseca
Oct 30, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Sofia DiasNicky J Welton
May 29, 2013·Nature Reviews. Endocrinology·Alice P S KongJuliana C N Chan
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Yu XuUNKNOWN 2010 China Noncommunicable Disease Surveillance Group
Mar 29, 2014·Chinese Journal of Integrative Medicine·Xin WangUNKNOWN Specialty Committee of Evaluation of Postmarketing Chinese Medicines of World Federation of Chinese Medicine Societies
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Amélie BeaudetPhil McEwan
Sep 15, 2014·The Lancet. Diabetes & Endocrinology·Juliana C N ChanGuang Ning
Jan 7, 2015·Expert Review of Cardiovascular Therapy·Georgina SposettiNoël C Barengo
Feb 24, 2015·Asia-Pacific Journal of Public Health·Hao WangLi Yuan
Sep 25, 2015·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Chen-Wei PanPei Wang
Jul 28, 2016·Diabetes/metabolism Research and Reviews·Jianping WengUNKNOWN Chinese Diabetes Society
Dec 28, 2016·Diabetes, Obesity & Metabolism·Phil McEwanMarc Evans
Apr 19, 2017·Annals of Internal Medicine·René Rodriguez-Gutierrez, Victor M Montori
Jun 28, 2017·JAMA : the Journal of the American Medical Association·Limin WangLinhong Wang
Jan 25, 2018·Diabetes, Obesity & Metabolism·Sudesna ChatterjeeKamlesh Khunti
Aug 23, 2018·Journal of Comparative Effectiveness Research·Bin WuHaixiang Wu
Sep 20, 2018·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Y JiaS-W Leung

❮ Previous
Next ❯

Citations

Jul 24, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Jose LealPhilip Clarke

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation

Software Mentioned

COMT

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.